Colchicine use in children and adolescents with familial Mediterranean fever: Literature review and consensus statement

Pediatrics

Volumn 119, Issue 2, 2007, Pages

  Kallinich, Tilmann ^a   Haffner, Dieter ^b   Niehues, Tim ^c   Huss, Kristina ^d   Lainka, Elke ^e   Neudorf, Ulrich ^e   Schaefer, Christof ^f   Stojanov, Silvia ^d,j   Timmann, Christian ^g   Keitzer, Rolf ^a   Ozdogan, Huri ^h   Ozen, Seza ⁱ  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f Berliner Betrieb für Zentrale Gesundheitliche Aufgaben ^*  (Germany)

^g BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^h ISTANBUL UNIVERSITY   (Turkey)

ⁱ HACETTEPE UNIVERSITY   (Turkey)

^j NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

more..

Author keywords

Colchicine; Evidence based guidelines; Familial Mediterranean fever; Treatment

Indexed keywords

ALPHA INTERFERON; C REACTIVE PROTEIN; COLCHICINE; CYTOSKELETON PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; HERBACEOUS AGENT; INFLIXIMAB; PROTEIN MEFV; SERUM AMYLOID A; THALIDOMIDE; UNCLASSIFIED DRUG;

ALOPECIA; ANGIONEUROTIC EDEMA; APLASTIC ANEMIA; AWARENESS; BREAST FEEDING; CAREGIVER; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DIARRHEA; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; EPISTAXIS; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FAMILIAL MEDITERRANEAN FEVER; FEMALE FERTILITY; GASTROINTESTINAL DISEASE; GENE MUTATION; GEOGRAPHY; HEMOLYTIC ANEMIA; HUMAN; INFLAMMATION; LACTOSE INTOLERANCE; LEUKOPENIA; MALE FERTILITY; MEDICAL LITERATURE; MUSCLE WEAKNESS; MUTAGENIC ACTIVITY; MYALGIA; MYOPATHY; NAUSEA; NEUROPATHY; NEUTROPENIA; PANCYTOPENIA; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; PURPURA; REVIEW; SIDE EFFECT; SPONTANEOUS ABORTION; STEATORRHEA; TERATOGENESIS; THROMBOCYTOPENIA; THROMBOCYTOSIS; TOXICITY; TREATMENT OUTCOME; URTICARIA; WEIGHT GAIN;

ADOLESCENT; CHILD; COLCHICINE; FAMILIAL MEDITERRANEAN FEVER; HUMANS;

EID: 33947186204     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-1434     Document Type: Review

References (142)

1. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever: a survey of 470 cases and review of the literature. Am J Med. 1967;43:227-253
2. Feldmann W. Evidence-Based Pediatrics. 1st ed. Hamilton, Ontario, Canada: BC Decker; 2000
3. Ben Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum. 1998;28:48-59
4. Ertel NH, Mittler JC, Akgun S, Wallace SL. Radioimmunoassay for colchicine in plasma and urine. Science. 1976;193:233-235
5. Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ. Colchicine biotransformation by human liver microsomes: identification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochem Pharmacol. 1997;53:111-116
6. Hunter AL, Klaassen CD. Biliary excretion of colchicine. J Pharmacol Exp Ther. 1975;192:605-617
7. Sabouraud A, Rochdi M, Urtizberea M, Christen MO, Achtert G, Scherrmann JM. Pharmacokinetics of colchicine: a review of experimental and clinical data. Z Gastroenterol. 1992;30(suppl 1):35-39
8. Rochdi M, Sabouraud A, Girre C, Venet R, Scherrmann JM. Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. Eur J Clin Pharmacol. 1994;46:351-354
9. Ferron GM, Rochdi M, Jusko WJ, Scherrmann JM. Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J Clin Pharmacol. 1996;36:874-883
10. Girre C, Thomas G, Scherrmann JM, Crouzette J, Fournier PE. Model-independent pharmacokinetics of colchicine after oral administration to healthy volunteers. Fundam Clin Pharmacol. 1989;3:537-543
11. Thomas G, Girre C, Scherrmann JM, Francheteau P, Steimer JL. Zero-order absorption and linear disposition of oral colchicine in healthy volunteers. Eur J Clin Pharmacol. 1989;37:79-84
12. Chappey ON, Niel E, Dervichian M, et al. Colchicine disposition in human leukocytes after single and multiple oral administration. Clin Pharmacol Ther. 1993;54:360-367
13. Ben Chetrit E, Scherrmann JM, Zylber-Katz E, Levy M. Colchicine disposition in patients with familial Mediterranean fever with renal impairment. J Rheumatol. 1994;21:710-713
14. Leighton JA, Bay MK, Maldonado AL, Schenker S, Speeg KV. Colchicine clearance is impaired in alcoholic cirrhosis. Hepatology. 1991;14:1013-1015
15. Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972;287:1302
16. Eliakim M, Light A. Letter: colchicine-aspirin for recurrent polyserositis (familial Mediterranean fever). Lancet. 1973;2(7841):1333
17. Manialawi M. Colchicine for familial Mediterranean fever. N Engl J Med. 1973;289:752
18. Hassan A, Trabolsi B, Farid Z. Letter: colchicine for familial Mediterranean fever. N Engl J Med. 1974;290:973
19. Hovsepian JM. Letter: colchicine for familial Mediterranean fever. N Engl J Med. 1974;290:973
20. Reimann HA. Letter: colchicine for familial Mediterranean fever. N Engl J Med. 1974;290:973
21. Ozkan E, Okur O, Ekmekci A, et al. A new approach to the treatment of periodic fever. Med Bull Istanbul Med Fac. 1972;5:44-49
22. Goldstein RC, Schwabe AD. Prophylactic colchicine therapy in familial Mediterranean fever: a controlled, double-blind study. Ann Intern Med. 1974;81:792-794
23. Zemer D, Revach M, Pras MA, et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N Engl J Med. 1974;291:932-934
24. Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW. Colchicine therapy for familial Mediterranean fever: a double-blind trial. N Engl J Med. 1974;291:934-937
25. Levy M, Eliakim M. Long-term colchicine prophylaxis in familial Mediterranean fever. Br Med J. 1977;2(6090):808
26. Lehman TJ, Peters RS, Hanson V, Schwabe A. Long-term colchicine therapy of familial Mediterranean fever. J Pediatr. 1978;93:876-878
27. Branski D, Gross-Kieselstein E, Abrahamov A. Colchicine therapy in familial Mediterranean fever: prophylactic benefit in 6 childhood patients. Clin Pediatr (Phila). 1978;17:14-15
28. Majeed HA, Carroll JE, Khuffash FA, Hijazi Z. Long-term colchicine prophylaxis in children with familial Mediterranean fever (recurrent hereditary polyserositis). J Pediatr. 1990;116:997-999
29. Gedalia A, Adar A, Gorodischer R. Familial Mediterranean fever in children. J Rheumatol Suppl. 1992;35:1-9
30. Zemer D, Livneh A, Danon YL, Pras M, Sohar E. Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum. 1991;34:973-977
31. Majeed HA, Barakat M. Familial Mediterranean fever (recurrent hereditary polyserositis) in children: analysis of 88 cases. Eur J Pediatr. 1989;148:636-641
32. Ertekin V, Selimoglu MA, Pirim I. Familial Mediterranean fever in a childhood population in eastern Turkey. Pediatr Int. 2005;47:640-644
33. Rawashdeh MO, Majeed HA. Familial Mediterranean fever in Arab children: the high prevalence and gene frequency. Eur J Pediatr. 1996;155:540-544
34. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med. 1986;314:1001-1005
35. Majeed HA, Carroll JE, Khuffash FA, Hijazi Z. Familial Mediterranean fever in children: the expanded clinical profile [published correction appears in QJM. 1999;92:545]. QJM. 1999;92:309-318
36. Padeh S. Periodic fever syndromes. Pediatr Clin North Am. 2005;52:577-609
37. Saatci U, Ozen S, Ozdemir S, et al. Familial Mediterranean fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr. 1997;156:619-623
38. Livneh A, Zemer D, Langevitz P, Laor A, Sohar E, Pras M. Colchicine treatment of AA amyloidosis of familial Mediterranean fever: an analysis of factors affecting outcome. Arthritis Rheum. 1994;37:1804-1811
39. Skrinskas G, Bear RA, Magil A, Lee KY. Colchicine therapy for nephrotic syndrome due to familial Mediterranean fever. Can Med Assoc J. 1977;117:1416-1417
40. Ravid M, Robson M, Kedar I. Prolonged colchicine treatment in four patients with amyloidosis. Ann Intern Med. 1977;87:568-570
41. Familial Mediterranean fever and amyloidosis. Kidney Int. 1981;20:676-685
42. Herlin T, Storm K, Hamborg-Petersen B. Remission of progressive renal failure in familial Mediterranean fever during colchicine treatment. Arch Dis Child. 1985;60:477-479
43. Sirera G, Tural C, Bonal J, Caralps A. Regression of nephrotic syndrome in amyloidosis secondary to familial Mediterranean fever during maintenance therapy using colchicine [in Spanish]. Med Clin (Barc). 1989;92:757
44. Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore). 1991;70:246-256
45. Zemer D, Livneh A, Langevitz P. Reversal of the nephrotic syndrome by colchicine in amyloidosis of familial Mediterranean fever. Ann Intern Med. 1992;116:426
46. Zemer D, Livneh A, Pras M, Sohar E. Familial Mediterranean fever in the colchicine era: the fate of one family. Am J Med Genet. 1993;45:340-344
47. Rozenbaum M, Rosner I. Regression of amyloidosis with colchicine in familial Mediterranean fever in an Ashkenazi patient. Clin Exp Rheumatol. 1995;13:126
48. Simsek B, Islek I, Simsek T, Kucukoduk S, Cengiz K. Regression of nephrotic syndrome due to amyloidosis secondary to familial Mediterranean fever following colchicine treatment. Nephrol Dial Transplant. 2000;15:281-282
49. Ozkaya N, Yalcinkaya F. Colchicine treatment in children with familial Mediterranean fever. Clin Rheumatol. 2003;22:314-317
50. Livneh A, Zemer D, Siegal B, Laor A, Sohar E, Pras M. Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever. Nephron. 1992;60:418-422
51. Wallace SL, Ertel NH. Occupancy approach to colchicine dosage. Lancet. 1970;2(7685):1250-1251
52. Korkmaz C, Ozdogan H, Kasapcopur O, Yazici H. Acute phase response in familial Mediterranean fever. Ann Rheum Dis. 2002;61:79-81
53. Duzova A, Bakkaloglu A, Besbas N, et al. Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol. 2003;21:509-514
54. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358:24-29
55. Oner A, Erdogan O, Demircin G, Bulbul M, Memis L. Efficacy of colchicine therapy in amyloid nephropathy of familial Mediterranean fever. Pediatr Nephrol. 2003;18:521-526
56. International FMF consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90:797-807
57. Shohat M, Magal N, Shohat T, et al. Phenotype-genotype correlation in familial Mediterranean fever: evidence for an association between Met694Val and amyloidosis. Eur J Hum Genet. 1999;7:287-292
58. Cazeneuve C, Sarkisian T, Pecheux C, et al. MEFV-gene analysis in Armenian patients with familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. Am J Hum Genet. 1999;65:88-97
59. Livneh A, Langevitz P, Shinar Y, et al. MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. Amyloid. 1999;6:1-6
60. Mimouni A, Magal N, Stoffman N, et al. Familial Mediterranean fever: effects of genotype and ethnicity on inflammatory attacks and amyloidosis. Pediatrics. 2000;105(5). Available at: www.pediatrics.org/cgi/content/ full/105/5/e70
61. Shinar Y, Livneh A, Langevitz, et al. Genotype-phenotype assessment of common genotypes among patients with familial Mediterranean fever. J Rheumatol. 2000;27:1703-1707
62. Ben Chetrit E, Backenroth R. Amyloidosis induced, end stage renal disease in patients with familial Mediterranean fever is highly associated with point mutations in the MEFV gene. Ann Rheum Dis. 2001;60:146-149
63. Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum. 2003;48:1149-1155
64. Medlej-Hashim M, Delague V, Chouery E, et al. Amyloidosis in familial Mediterranean fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects. BMC Med Genet. 2004;5:4
65. Yalcinkaya F, Akar N, Misirlioglu M. Familial Mediterranean fever: amyloidosis and the Val726Ala mutation. N Engl J Med. 1998;338:993-994
66. Yalcinkaya F, Cakar N, Misirlioglu M, et al. Genotype-phenotype correlation in a large group of Turkish patients with familial Mediterranean fever: evidence for mutation-independent amyloidosis [published correction appears in Rheumatology (Oxford). 2000;39:1170]. Rheumatology (Oxford). 2000;9:67-72
67. Ozen S. Renal amyloidosis in familial Mediterranean fever. Kidney Int. 2004;65:1118-1127
68. Atagunduz MP, Tuglular S, Kantarci G, Akoglu E, Direskeneli H. Association of FMF-related (MEFV) point mutations with secondary and FMF amyloidosis. Nephron Clin Pract. 2004;96:c131-c135
69. Cazeneuve C, Ajrapetyan H, Papin S, et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet. 2000;67:1136-1143
70. Yilmaz E, Balci B, Kutlay S, et al. Analysis of the modifying effects of SAA1, SAA2 and TNF-alpha gene polymorphisms on development of amyloidosis in FMF patients. Turk J Pediatr. 2003;45:198-202
71. Akar S, Soyturk M, Onen F, Tunca M. Serum amyloid A1 and tumor necrosis factor-alpha alleles in Turkish familial Mediterranean fever patients with and without amyloidosis. Amyloid. 2003;10:12-16
72. Bakkaloglu A, Duzova A, Ozen S, et al. Influence of Serum Amyloid A (SAA1) and SAA2 gene polymorphisms on renal amyloidosis, and on SAA/C-reactive protein values in patients with familial Mediterranean fever in the Turkish population. J Rheumatol. 2004;31:1139-1142
73. Montseny JJ, Meyrier A, Gherardi RK. Colchicine toxicity in patients with chronic renal failure. Nephrol Dial Transplant. 1996;11:2055-2058
74. Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy. N Engl J Med. 1987;316:1562-1568
75. Boomershine KH. Colchicine-induced rhabdomyolysis. Ann Pharmacother. 2002;36:824-826
76. Schiff D, Drislane FW. Rapid-onset colchicine myoneuropathy. Arthritis Rheum. 1992;35:1535-1536
77. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol. 1991;18:264-269
78. Anderson-Haag T, Patel B. Safety of colchicine in dialysis patients. Semin Dial. 2003;16:412-413
79. Lange U, Schumann C, Schmidt KL. Aspects of colchicine therapy. 1: Pharmacology, toxicology, classic indications [in German]. Z Arztl Fortbild Qualitatssich. 2002;96:59-63
80. Wallace SL, Singer JZ. Review: systemic toxicity associated with the intravenous administration of colchicine - guidelines for use. J Rheumatol. 1988;15:495-499
81. Kaplan MM, Alling DW, Zimmerman HJ, et al. A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med. 1986;315:1448-1454
82. Kershenobich D, Uribe M, Suarez GI, Mata JM, Perez-Tamayo R, Rojkind M. Treatment of cirrhosis with colchicine: a double-blind randomized trial. Gastroenterology. 1979;77:532-536
83. Kogan A, Shinar Y, Lidar M, et al. Common MEFV mutations among Jewish ethnic groups in Israel: high frequency of carrier and phenotype III states and absence of a perceptible biological advantage for the carrier state. Am J Med Genet. 2001;102:272-276
84. Achtert G, Scherrmann JM, Christen MO. Pharmacokinetics/bioavailability of colchicine in healthy male volunteers. Eur J Drug Metab Pharmacokinet. 1989;14:317-322
85. Ehrenfeld M, Levy M, Sharon P, Rachmilewitz D, Eliakim M. Gastrointestinal effects of long-term colchicine therapy in patients with recurrent polyserositis (familial Mediterranean fever). Dig Dis Sci. 1982;27:723-727
86. Fradkin A, Yahav J, Zemer D, Jonas A. Colchicine-induced lactose malabsorption in patients with familial Mediterranean fever. Isr J Med Sci. 1995;31:616-620
87. Sayarlioglu M, Sayarlioglu H, Ozen S, Erkoc R, Gul A. Colchicine-induced myopathy in a teenager with familial Mediterranean fever. Ann Pharmacother. 2003;37:1821-1824
88. Harel L, Mukamel M, Amir J, Straussberg R, Cohen AH, Varsano I. Colchicine-induced myoneuropathy in childhood. Eur J Pediatr. 1998;157:853-855
89. Dixon AJ, Wall GC. Probable colchicine-induced neutropenia not related to intentional overdose. Ann Pharmacother. 2001;35:192-195
90. Ferrannini E, Pentimone F. Marrow aplasia following colchicine treatment for gouty arthritis. Clin Exp Rheumatol. 1984;2:173-175
91. Ben Chetrit E, Navon P. Colchicine-induced leukopenia in a patient with familial Mediterranean fever: the cause and a possible approach. Clin Exp Rheumatol. 2003;21:S38-S40
92. Guven AG, Bahat E, Akman S, Artan R, Erol M. Late diagnosis of severe colchicine intoxication. Pediatrics. 2002;109:971-973
93. Savgan-Gurol E, Kasapcopur O, Hatemi S, et al. Growth and IGF-1 levels of children with familial Mediterranean fever on colchicine treatment. Clin Exp Rheumatol. 2001;19(5 suppl 24):S72-S75
94. Zung A, Barash G, Zadik Z, Barash J. Familial Mediterranean fever and growth: effect of disease severity and colchicine treatment. J Pediatr Endocrinol Metab. 2006;19:155-160
95. Leighton JA, Bay MK, Maldonado AL, Johnson RF, Schenker S, Speeg KV. The effect of liver dysfunction on colchicine pharmacokinetics in the rat. Hepatology. 1990;11:210-215
96. Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P. Acute colchicine intoxication during clarithromycin administration. Ann Pharmacother. 2004;38:2074-2077
97. Menta R, Rossi E, Guariglia A, David S, Cambi V. Reversible acute cyclosporin nephrotoxicity induced by colchicine administration. Nephrol Dial Transplant. 1987;2:380-381
98. Goldbart A, Press J, Sofer S, Kapelushnik J. Near fatal acute colchicine intoxication in a child: a case report. Eur J Pediatr. 2000;159:895-897
99. Granat M, Tur-Kaspa I, Zylber-Katz E, Schenker JG. Reduction of peritoneal adhesion formation by colchicine: a comparative study in the rat. Fertil Steril. 1983;40:369-372
100. Ismajovich B, Zemer D, Revach M, Serr DM, Sohar E. The causes of sterility in females with familial Mediterranean fever. Fertil Steril. 1973;24:844-847
101. Zemer D, Pras M, Sohar E, Gafni J. Letter: colchicine in familial Mediterranean fever. N Engl J Med. 1976;294:170-171
102. Ehrenfeld M, Brzezinski A, Levy M, Eliakim M. Fertility and obstetric history in patients with familial Mediterranean fever on long-term colchicine therapy. Br J Obstet Gynaecol. 1987;94:1186-1191
103. Rabinovitch O, Zemer D, Kukia E, Sohar E, Mashiach S. Colchicine treatment in conception and pregnancy: two hundred thirty-one pregnancies in patients with familial Mediterranean fever. Am J Reprod Immunol. 1992;28:245-246
104. Cabili S, Livneh A, Zemer D, Rabinovitch O, Pras M. The effect of pregnancy on renal function in amyloidosis of familial Mediterranean fever. Am J Reprod Immunol. 1992;28:243-244
105. Sanders CL, Lucas MJ. Renal disease in pregnancy. Obstet Gynecol Clin North Am. 2001;28:593-600
106. Ben Chetrit E, Levy M. Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum. 1991;20:241-246
107. Cohen MM, Levy M, Eliakim M. A cytogenic evaluation of long-term colchicine therapy in the treatment of familial Mediterranean fever (FMF). Am J Med Sci. 1977;274:147-152
108. Akar S, Soyturk M, Onen F, Tunca M. The relations between attacks and menstrual periods and pregnancies of familial Mediterranean fever patients. Rheumatol Int. 2006;26:676-679
109. Tutuncu L, Atasoyu EM, Evrenkaya R, Mungen E. Familial Mediterranean fever-related nephrotic syndrome and successful full-term pregnancy. Arch Med Res. 2006;37:178-180
110. Barkai G, Meital Y, Chetrit A. Clinical and chromosomal outcome following colchicine exposure before and during pregnancy. Paper presented at: the 11th annual meeting of the European Network of Teratology Information Services. September 19-21, 2000; Jerusalem, Israel
111. Ben Chetrit E, Levy M. Reproductive system in familial Mediterranean fever: an overview. Ann Rheum Dis. 2003;62:916-919
112. Berkenstadt M, Weisz B, Cuckle H, Di-Castro M, Guetta E, Barkai G. Chromosomal abnormalities and birth defects among couples with colchicine treated familial Mediterranean fever. Am J Obstet Gynecol. 2005;193:1513-1516
113. Ben-Chetrit E, Berkun Y, Ben-Chetrit E, Ben-Chetrit A. The outcome of pregnancy in the wives of men with familial Mediterranean fever treated with colchicine. Semin Arthritis Rheum. 2004;34:549-552
114. Ben Chetrit E, Scherrmann JM, Levy M. Colchicine in breast milk of patients with familial Mediterranean fever. Arthritis Rheum. 1996;39:1213-1217
115. Milunsky JM. Breast-feeding during colchicine therapy for familial Mediterranean fever. J Pediatr. 1991;19:164
116. Guillonneau M, Aigrain EJ, Galliot M, Binet MH, Darbois Y. Colchicine is excreted at high concentrations in human breast milk. Eur J Obstet Gynecol Reprod Biol. 1995;61:177-178
117. Ben Chetrit A, Ben Chetrit E, Nitzan R, Ron M. Colchicine inhibits spermatozoal motility in vitro. Int J Fertil Menopausal Stud. 1993;38:301-304
118. Haimov-Kochman R, Ben Chetrit E. The effect of colchicine treatment on sperm production and function: a review. Hum Reprod. 1998;13:360-362
119. Bremner WJ, Paulsen CA. Colchicine and testicular function in man. N Engl J Med. 1976;294:1384-1385
120. Levy M, Yaffe C. Testicular function in patients with familial Mediterranean fever on long-term colchicine treatment. Fertil Steril. 1978;29:667-668
121. Ben Chetrit E, Backenroth R, Haimov-Kochman R, Pizov G. Azoospermia in familial Mediterranean fever patients: the role of colchicine and amyloidosis. Ann Rheum Dis. 1998;57:259-260
122. Stapczynski JS, Rothstein RJ, Gaye WA, Niemann JT. Colchicine overdose: report of two cases and review of the literature. Ann Emerg Med. 1981;10:364-369
123. MacLeod JG, Philips L. Hypersensitivity to colchicine. Ann Rheum Dis. 1947;6:224-229
124. Baud FJ, Sabouraud A, Vicaut E, et al. Brief report: treatment of severe colchicine overdose with colchicine-specific Fab fragments. N Engl J Med. 1995;332:642-645
125. van der Naalt J, Haaxma-Reiche H, van den Berg AP, Hazenberg BP, Molenaar WM. Acute neuromyopathy after colchicine treatment. Ann Rheum Dis. 1992;51:1267-1268
126. Tenenbein M, Cohen S, Sitar DS. Efficacy of ipecac-induced emesis, orogastric lavage, and activated charcoal for acute drug overdose. Ann Emerg Med. 1987;16:838-841
127. Putterman C, Ben Chetrit E, Caraco Y, Levy M. Colchicine intoxication: clinical pharmacology, risk factors, features, and management. Semin Arthritis Rheum. 1991;21:143-155
128. Chyka PA, Seger D, Krenzelok EP, Vale JA; American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Position paper: single-dose activated charcoal. Clin Toxicol (Phila). 2005;43:61-87
129. Maxwell MJ, Muthu P, Pritty PE. Accidental colchicine overdose: a case report and literature review. Emerg Med J. 2002;19:265-267
130. Critchley JA, Critchley LA, Yeung EA, et al. Granulocyte-colony stimulating factor in the treatment of colchicine poisoning. Hum Exp Toxicol. 1997;16:229-232
131. Mullins ME, Robertson DG, Norton RL. Troponin I as a marker of cardiac toxicity in acute colchicine overdose. Am J Emerg Med. 2000;18:743-744
132. Schwabe AD, Peters RS. Familial Mediterranean fever in Armenians: analysis of 100 cases. Medicine (Baltimore). 1974;53:453-462
133. Tunca M, Tankurt E, Akbaylar Akpinar H, Akar S, Hizli N, Gonen O. The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study. Br J Rheumatol. 1997;36:1005-1008
134. Tunca M, Akar S, Soyturk M, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: a double-blind, placebo-controlled trial. Clin Exp Rheumatol. 2004;22:S37-S40
135. Lidar M, Kedem R, Langevitz P, Pras M, Livneh A. Intravenous colchicine for treatment of patients with familial Mediterranean fever unresponsive to oral colchicine. J Rheumatol. 2003;30:2620-2623
136. Seyahi E, Ozdogan H, Masatlioglu S, Yazici H. Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient. Clin Exp Rheumatol. 2002;20(4 suppl 26):S43-S44
137. Calguneri M, Apras S, Ozbalkan Z, et al. The efficacy of continuous interferon alpha administration as an adjunctive agent to colchicine-resistant familial Mediterranean fever patients. Clin Exp Rheumatol. 2004;22(4 suppl 34):S41-S44
138. Daysal S, Akcil G, Goker B, Haznedaroglu S, Ercan N, Ozturk MA. Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis. Arthritis Rheum. 2005;53:146-147
139. Metyas S, Arkfeld DG, Forrester DM, Ehresmann GR. Infliximab treatment of familial Mediterranean fever and its effect on secondary AA amyloidosis. Clin Rheumatol. 2004;10:134-137
140. Amaryan G, Astvatsatryan V, Gabrielyan E, Panossian A, Panosyan V, Wikman G. Double-blind, placebo-controlled, randomized, pilot clinical trial of ImmunoGuard: a standardized fixed combination of Andrographis paniculata Nees, with Eleutherococcus senticosus Maxim, Schizandra chinensis Bail. and Glycyrrhiza glabra L. extracts in patients with familial Mediterranean fever. Phytomedicine. 2003;10:271-285
141. Touitou I. Should patients with FMF undergo BMT? Blood. 2003;101:1205-1206
142. Touitou I, Ben-Chetrit E, Gershoni-Baruch R, et al. Allogenic bone marrow transplantation: not a treatment yet for familial Mediterranean fever. Blood. 2003;102:409